{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:59:51Z","timestamp":1793825991957,"version":"4.6.1"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Myelodysplastic syndrome (MDS) is a malignant clonal disorder originating from hematopoietic stem and progenitor cells and is characterized by ineffective hematopoiesis and a high propensity for transformation into acute leukemia. Research has indicated that the pathogenesis of MDS is closely linked to genetic mutations and that its progression may encompass multiple stages, including cytogenetic and molecular alterations, leading to the acquisition of oncogenic mutations. The widespread application of next-generation sequencing (NGS) technologies, including whole-genome sequencing, whole-exome sequencing, and RNA sequencing, has significantly improved our understanding of the genetic alterations and transcriptomic modifications underlying MDS. These technologies not only deepen our understanding of molecular mechanisms but also facilitate the identification of potential therapeutic targets and prognostic biomarkers. Consequently, the 2022 World Health Organization Classification and the International Consensus Classification have incorporated molecular features into the MDS classification system, and the Molecular International Prognostic Scoring System (IPSS-M) was introduced. This review aims to summarize the role of NGS in the precise diagnosis, classification, risk assessment, treatment selection, and evaluation of therapeutic effectiveness in MDS, with implications for advancing precision medicine in hematological malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bs9.0000000000000281","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:00:10Z","timestamp":1773172810000},"page":"e00281","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice"],"prefix":"10.1097","volume":"8","author":[{"given":"Ying-Ying","family":"Ma","sequence":"first","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Blood Diseases Institute, Xuzhou Medical University, Xuzhou 221002, China"},{"name":"Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu Province 221002, China"},{"name":"Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"1","key":"R1-20260310","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-022-01346-9","article-title":"Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.","volume":"15","author":"Mohty","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"R2-20260310","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3390\/curroncol31050175","article-title":"A brief overview of the molecular landscape of myelodysplastic neoplasms.","volume":"31","author":"Abdulbaki","year":"2024","journal-title":"Curr Oncol"},{"issue":"11","key":"R3-20260310","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","article-title":"Next-generation sequencing technologies: an overview.","volume":"82","author":"Hu","year":"2021","journal-title":"Hum Immunol"},{"key":"R4-20260310","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-1-0716-1920-9_22","article-title":"RNA-seq experiment and data analysis.","volume":"2418","author":"Withanage","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"4","key":"R5-20260310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies.","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"issue":"7","key":"R6-20260310","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"R7-20260310","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.16212","article-title":"The evolving role of next generation sequencing in myelodysplastic syndromes.","volume":"188","author":"Spaulding","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"R8-20260310","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers.","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"R9-20260310","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/10428194.2022.2080821","article-title":"Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.","volume":"63","author":"Lyu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"R10-20260310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia.","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"issue":"12","key":"R11-20260310","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation.","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"R12-20260310","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes.","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"11","key":"R13-20260310","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"49","key":"R14-20260310","doi-asserted-by":"crossref","first-page":"e2211429119","DOI":"10.1073\/pnas.2211429119","article-title":"Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.","volume":"119","author":"Cheng","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"R15-20260310","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/joim.12893","article-title":"Treatment of myelodysplastic syndrome in the era of next-generation sequencing.","volume":"286","author":"Tobiasson","year":"2019","journal-title":"J Intern Med"},{"issue":"7","key":"R16-20260310","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/diagnostics12071581","article-title":"Myelodysplastic syndrome: diagnosis and screening.","volume":"12","author":"Tria","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"21","key":"R17-20260310","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/bloodadvances.2018022434","article-title":"Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS.","volume":"3","author":"Thol","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"R18-20260310","first-page":"328","article-title":"Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.","volume":"53","author":"Hughes","year":"2021","journal-title":"Pathology (Phila)"},{"issue":"20","key":"R19-20260310","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"R20-20260310","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes.","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"R21-20260310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-024-01571-4","article-title":"A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.","volume":"17","author":"Xiao","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"11","key":"R22-20260310","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"11","key":"R23-20260310","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol"},{"issue":"7","key":"R24-20260310","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: how to avoid a Babylonian confusion of languages.","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"R25-20260310","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-022-01718-7","article-title":"Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"R26-20260310","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3343\/alm.2023.43.5.503","article-title":"Implications of the 5th edition of the World Health Organization classification and international consensus classification of myeloid neoplasm in myelodysplastic syndrome with excess blasts and acute myeloid leukemia.","volume":"43","author":"Lee","year":"2023","journal-title":"Ann Lab Med"},{"issue":"3","key":"R27-20260310","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.26799","article-title":"Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome\/acute myeloid leukemia based on the 2022 International Consensus Classification.","volume":"98","author":"Lee","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"R28-20260310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-024-01031-9","article-title":"Comparison of the 2022 World Health Organization classification and international consensus classification in myelodysplastic syndromes\/neoplasms.","volume":"14","author":"Lee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"R29-20260310","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41375-024-02157-2","article-title":"The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the D\u00fcsseldorf MDS registry and proposals for a merged classification.","volume":"38","author":"Nachtkamp","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"R30-20260310","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12308-023-00538-7","article-title":"The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.","volume":"16","author":"Bruehl","year":"2023","journal-title":"J Hematop"},{"issue":"3","key":"R31-20260310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18628","article-title":"Impact of the international consensus classification of myelodysplastic syndromes.","volume":"201","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"R32-20260310","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.19482","article-title":"Validation and comparison of 5th edition World Health Organization classification (WHO 2022) and international consensus classification proposals for MDS-SFB31.","volume":"205","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"issue":"21","key":"R33-20260310","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"3","key":"R34-20260310","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26812","article-title":"Comparison of the international consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"R35-20260310","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.molcel.2022.02.025","article-title":"Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.","volume":"82","author":"Biancon","year":"2022","journal-title":"Mol Cell"},{"issue":"21","key":"R36-20260310","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/bloodadvances.2020003007","article-title":"Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS.","volume":"4","author":"Stengel","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"R37-20260310","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes.","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"R38-20260310","doi-asserted-by":"crossref","first-page":"107433","DOI":"10.1016\/j.leukres.2023.107433","article-title":"The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.","volume":"136","author":"Khanna","year":"2024","journal-title":"Leuk Res"},{"issue":"12","key":"R39-20260310","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"Suppl 1","key":"R40-20260310","first-page":"2","article-title":"MDS classification\u2014do we still have to count blasts.","volume":"140","author":"Haferlach","year":"2022","journal-title":"Blood"},{"key":"R41-20260310","doi-asserted-by":"crossref","first-page":"610525","DOI":"10.3389\/fonc.2020.610525","article-title":"Integration analysis of JAK2 or RUNX1 mutation with bone marrow blast can improve risk stratification in the patients with lower risk myelodysplastic syndrome.","volume":"10","author":"Fang","year":"2021","journal-title":"Front Oncol"},{"key":"R42-20260310","doi-asserted-by":"crossref","first-page":"1014504","DOI":"10.3389\/fonc.2022.1014504","article-title":"Development and validation of a novel prognosis prediction model for patients with myelodysplastic syndrome.","volume":"12","author":"Liang","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"R43-20260310","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"15","key":"R44-20260310","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes.","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"R45-20260310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-023-00894-8","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.","volume":"13","author":"Lee","year":"2023","journal-title":"Blood Cancer J"},{"issue":"18","key":"R46-20260310","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2024024464","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141(14):1768-1772.","volume":"143","author":"Kewan","year":"2024","journal-title":"Blood"},{"issue":"24","key":"R47-20260310","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes.","volume":"42","author":"Tentori","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"R48-20260310","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/10428194.2023.2232491","article-title":"A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).","volume":"64","author":"Sabile","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"R49-20260310","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3343\/alm.2024.0089","article-title":"Assessing the relevance of non-molecular prognostic systems for myelodysplastic syndrome in the era of next-generation sequencing.","volume":"45","author":"Lincango","year":"2025","journal-title":"Ann Lab Med"},{"issue":"7","key":"R50-20260310","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41375-023-01910-3","article-title":"Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.","volume":"37","author":"Aguirre","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"R51-20260310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-022-00612-w","article-title":"Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.","volume":"12","author":"He","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"R52-20260310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-023-01431-7","article-title":"Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study.","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"R53-20260310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.","volume":"16","author":"Bahaj","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"R54-20260310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12967-024-05165-z","article-title":"Single-cell transcriptomics dissects the transcriptome alterations of hematopoietic stem cells in myelodysplastic neoplasms.","volume":"22","author":"Zeng","year":"2024","journal-title":"J Transl Med"},{"issue":"20","key":"R55-20260310","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-23-0538","article-title":"Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts.","volume":"29","author":"Todisco","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"26","key":"R56-20260310","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood.2023020079","article-title":"Clinical decision-making and treatment of myelodysplastic syndromes.","volume":"142","author":"Hellstr\u00f6m-Lindberg","year":"2023","journal-title":"Blood"},{"issue":"1","key":"R57-20260310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","article-title":"Myelodysplastic syndromes.","volume":"8","author":"Li","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"R58-20260310","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"11","key":"R59-20260310","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"R60-20260310","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11864-022-00965-1","article-title":"New approaches to myelodysplastic syndrome treatment.","volume":"23","author":"Bazinet","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"27","key":"R61-20260310","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2217\/fon-2023-0454","article-title":"Updates on risk stratification and management of lower-risk myelodysplastic syndromes\/neoplasms.","volume":"19","author":"Badar","year":"2023","journal-title":"Future Oncol"},{"issue":"9","key":"R62-20260310","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ajh.27410","article-title":"Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.","volume":"99","author":"Mittelman","year":"2024","journal-title":"Am J Hematol"},{"issue":"13","key":"R63-20260310","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.3390\/cancers13133296","article-title":"Myelodysplastic syndromes in the postgenomic era and future perspectives for precision medicine.","volume":"13","author":"Chanias","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10423","key":"R64-20260310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"R65-20260310","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.3390\/curroncol30070459","article-title":"Management of patients with lower-risk myelodysplastic neoplasms (MDS).","volume":"30","author":"Lucero","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"R66-20260310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study.","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"R67-20260310","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40265-024-02080-x","article-title":"Imetelstat: first approval.","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"13","key":"R68-20260310","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.34762","article-title":"Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: a multicenter, retrospective cohort study.","volume":"129","author":"Ma","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"R69-20260310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"R70-20260310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/gcc.22510","article-title":"Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.","volume":"57","author":"Li","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"R71-20260310","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.","volume":"21","author":"Smith","year":"2019","journal-title":"Nat Cell Biol"},{"key":"R72-20260310","doi-asserted-by":"crossref","first-page":"101055","DOI":"10.1016\/j.jbior.2024.101055","article-title":"Hyperactivation of NF-\u03baB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.","volume":"95","author":"Pellagatti","year":"2025","journal-title":"Adv Biol Regul"},{"issue":"12","key":"R73-20260310","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41408-022-00765-8","article-title":"Management of patients with lower-risk myelodysplastic syndromes.","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"15","key":"R74-20260310","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome.","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"R75-20260310","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"R76-20260310","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"R77-20260310","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"4","key":"R78-20260310","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-023-05462-5","article-title":"TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.","volume":"103","author":"Pereira","year":"2024","journal-title":"Ann Hematol"},{"issue":"14","key":"R79-20260310","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe Francophone des My\u00e9lodysplasies (GFM).","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"R80-20260310","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes.","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"R81-20260310","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies.","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"R82-20260310","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.26858","article-title":"Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.","volume":"98","author":"Siddiqui","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"R83-20260310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2013.191","article-title":"Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.","volume":"28","author":"Ok","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"R84-20260310","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"2","key":"R85-20260310","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"R86-20260310","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies.","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"R87-20260310","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation.","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"7954","key":"R88-20260310","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"8","key":"R89-20260310","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"R90-20260310","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00277-022-04853-4","article-title":"A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.","volume":"101","author":"Sekeres","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"R91-20260310","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1038\/s41467-022-35192-7","article-title":"The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes.","volume":"13","author":"Berastegui","year":"2022","journal-title":"Nat Commun"},{"issue":"21","key":"R92-20260310","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.3390\/cancers15215170","article-title":"The evolving landscape: exploring the future of myelodysplastic syndrome treatment with Dr. Rami Komrokji.","volume":"15","author":"Jackewicz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"R93-20260310","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/joim.13697","article-title":"Novel precision medicine approaches and treatment strategies in hematological malignancies.","volume":"294","author":"Rosenquist","year":"2023","journal-title":"J Intern Med"},{"issue":"7","key":"R94-20260310","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation.","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"R95-20260310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J"},{"key":"R96-20260310","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"issue":"3","key":"R97-20260310","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.19614","article-title":"Monitoring molecular changes in the management of myelodysplastic syndromes.","volume":"205","author":"Duployez","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"R98-20260310","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"R99-20260310","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"key":"R100-20260310","doi-asserted-by":"crossref","first-page":"700234","DOI":"10.3389\/fonc.2021.700234","article-title":"The prognostic value of early detection of minimal residual disease as defined by flow cytometry and gene mutation clearance for myelodysplastic syndrome patients after myeloablative allogeneic hematopoietic stem-cell transplantation.","volume":"11","author":"Hou","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"R101-20260310","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome.","volume":"379","author":"Duncavage","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"R102-20260310","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3390\/jcm8122077","article-title":"Simultaneous monitoring of mutation and chimerism using next-generation sequencing in myelodysplastic syndrome.","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"issue":"38","key":"R103-20260310","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci Adv"},{"issue":"11","key":"R104-20260310","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.5858\/arpa.2016-0501-RA","article-title":"Review of clinical next-generation sequencing.","volume":"141","author":"Yohe","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R105-20260310","doi-asserted-by":"crossref","first-page":"103200","DOI":"10.1016\/j.dnarep.2021.103200","article-title":"Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures.","volume":"107","author":"Abbasi","year":"2021","journal-title":"DNA Repair (Amst)"},{"issue":"5","key":"R106-20260310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/biom14050568","article-title":"The third-generation sequencing challenge: novel insights for the omic sciences.","volume":"14","author":"Scarano","year":"2024","journal-title":"Biomolecules"},{"issue":"9","key":"R107-20260310","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41576-023-00600-1","article-title":"Beyond assembly: the increasing flexibility of single-molecule sequencing technology.","volume":"24","author":"Hook","year":"2023","journal-title":"Nat Rev Genet"},{"key":"R108-20260310","doi-asserted-by":"crossref","first-page":"769753","DOI":"10.3389\/fonc.2021.769753","article-title":"Why single-cell sequencing has promise in MDS.","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"R109-20260310","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/ijc.35100","article-title":"Applications of nanopore sequencing in precision cancer medicine.","volume":"155","author":"Dyshlovoy","year":"2024","journal-title":"Int J Cancer"},{"issue":"2","key":"R110-20260310","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/clinchem\/hvac180","article-title":"Comparison of single molecule, real-time sequencing and nanopore sequencing for analysis of the size, end-motif, and tissue-of-origin of long cell-free DNA in plasma.","volume":"69","author":"Yu","year":"2023","journal-title":"Clin Chem"},{"issue":"5","key":"R111-20260310","doi-asserted-by":"crossref","first-page":"110671","DOI":"10.1016\/j.ygeno.2023.110671","article-title":"Spatial transcriptomics: technologies, applications and experimental considerations.","volume":"115","author":"Wang","year":"2023","journal-title":"Genomics"},{"issue":"6","key":"R112-20260310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41582-023-00809-y","article-title":"Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease.","volume":"19","author":"Piwecka","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"R113-20260310","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41556-024-01537-1","article-title":"Real-time and programmable transcriptome sequencing with PROFIT-seq.","volume":"26","author":"Zhang","year":"2024","journal-title":"Nat Cell Biol"},{"issue":"8","key":"R114-20260310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","article-title":"Methods and applications for single-cell and spatial multi-omics.","volume":"24","author":"Vandereyken","year":"2023","journal-title":"Nat Rev Genet"}],"container-title":["Blood Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:00:22Z","timestamp":1773172822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":114,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bs9.0000000000000281","relation":{},"ISSN":["2543-6368"],"issn-type":[{"value":"2543-6368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"2025-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}